← Oncology Approval Tracker

FDA DECISION ·

Keytruda Qlex

pembrolizumab + berahyaluronidase alfa-pmph · Merck

Accelerated approvalNew formulationTMB-high solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Oct 16, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Subcutaneous treatment for adults and children age 12 years or older with unresectable or metastatic solid tumors that are TMB-high (at least 10 mutations per megabase) by an FDA-approved test, after progression on prior treatment with no satisfactory alternatives.

LAMPGEN ANALYSIS

Why it matters

The new formulation carried a distinct accelerated approval for the tumor-agnostic TMB-high use.

What research teams should watch

Use the correct tumor mutational burden assay and threshold and keep the formulation-specific indication linked to its confirmatory status.

PRIMARY RECORDS

Sources